Jun 15, 2017 — TUCSON, Ariz., (June 14, 2017) — Accelerate Diagnostics, Inc. showcased new data presented at ASM Microbe 2017 on the potential clinical and workflow benefits of faster susceptibility results using the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit. The data comes from external studies across 11 healthcare institutions representing 1,300 samples, and compares the performance […]
Accelerate Diagnostics announces sizeable release of data at ASM Microbe 2017
May 30, 2017 — Accelerate Diagnostics, Inc. today announced that new data from 11 healthcare institutions covering more than 1,200 samples will be presented at the upcoming annual meeting of the American Society for Microbiology – ASM Microbe in New Orleans, LA.
Accelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering
May 15, 2017 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock today, upsized from the original share offering of 2,500,000 shares of common stock, at a previously disclosed public offering price of $28.85 per share. The gross proceeds to Accelerate Diagnostics from the offering are approximately $79.3 million before deducting underwriting commissions and discounts, and estimated offering expenses payable by the company.
Accelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017
May 03, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending March 31, 2017 including signed customer evaluation contracts covering 169 instruments, 22 additional instruments converted into revenue generating placements, and revenue growth exceeding 325% of the same period in the prior year.
See all news
Enter your email address below for access to photos, logos and videos.
Connect with us
October 4–8, 2017
Stay up to date with Accelerate by joining our mailing list.Sign up today
June 1–5, 2017
May 10–13, 2017
Friday, May 5, 2017
April 22–25, 2017
March 26–28, 2017
March 21–27, 2017
Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.